公司问答丨艾迪药业：公司普药业务增速较快主要来自于番泻叶颗粒销量的增加

Core Insights - The company anticipates a 61% growth in its generic drug revenue for the first half of 2025, driven primarily by increased sales of its unique product, Senna Leaf Granules [1] Company Performance - The significant revenue growth in the generic drug segment is attributed to the rising demand for Senna Leaf Granules, which is used for treating constipation and promoting bowel movements [1]